Summary: Cardinal Health, the second largest U.S. drug distributor by revenue, announced plans to sell its manufacturing/packaging unit and focus on hospital and pharmacy customers. Proceeds from the manufacturing unit, which generates $1.8 billion in annual revenue, will be used to buy back up to $3 billion in company stock. The manufacturing unit employs about 10,000 at more than 30 worldwide sites. Earlier in the month Cardinal sold its healthcare marketing services business to a private equity firm. Cardinal stock rose 4.5% on news of the planned sale and buyback program and Deutsche Bank upgraded the stock, stating the manufacturing unit "has been a drag on the company's overall performance."
Related links: Media coverage: WSJ, Reuters. Commentary: Multiple Symptoms of Excessive Pay at Cardinal Health, Jim Cramer's take on Cardinal Health
Potentially impacted stocks and ETFs: Cardinal Health (CAH) • Competitors: AmerisourceBergen (ABC), McKesson (MCK)
Seeking Alpha is not affiliated with Bloomberg.